Cancer Family
Endocrine Neoplasm
CI-CAN-00000015Explore in graph →
Non-malignant764 active trials16 approved drugs64 evidence items
- NCIt
- C3010
Loading cancer entity…
Cancer Family
CI-CAN-00000015Explore in graph →
Clinical trials
2,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04711135 | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs(NETTER-P) | active not recruiting | Phase 2 | 11 | Advanced Accelerator ApplicationsINDUSTRY | 5 | Feb 12, 2026 | clinicaltrials |
| NCT02143726 | Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer | active not recruiting | Phase 2 | 35 | Alliance for Clinical Trials in OncologyOTHER |
| 1 |
| Feb 11, 2026 |
| clinicaltrials |
| NCT06943235 | Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC) | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07404176 | Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors(TENET) | recruiting | Phase 2 | 20 | Tata Memorial HospitalOTHER_GOV | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07398560 | Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study | not yet recruiting | Phase 2 | 47 | The Third Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors(Tamarack) | terminated | Phase 2 | 192 | MacroGenicsINDUSTRY | 9 | Feb 9, 2026 | clinicaltrials |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | terminated | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06790589 | COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer | not yet recruiting | Phase 2 | 70 | AHS Cancer Control AlbertaOTHER | 0 | Feb 6, 2026 | clinicaltrials |
| NCT06939036 | Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )(SANTANA-225) | terminated | Phase 1 / Phase 2 | 2 | Ariceum Therapeutics GmbHINDUSTRY | 2 | Feb 5, 2026 | clinicaltrials |
| NCT07388875 | Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC(SKB264-ANLO) | not yet recruiting | Phase 2 | 30 | China Medical University, ChinaOTHER | 0 | Feb 5, 2026 | clinicaltrials |
| NCT07381543 | Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone | not yet recruiting | Phase 2 | 76 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06440850 | Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | recruiting | Phase 2 | 21 | City of Hope Medical CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04187404 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma(Spencer) | terminated | Phase 1 / Phase 2 | 70 | EnteromeINDUSTRY | 8 | Jan 30, 2026 | clinicaltrials |
| NCT06055439 | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | recruiting | Phase 1 / Phase 2 | 135 | Chimeric TherapeuticsINDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07376499 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | not yet recruiting | Phase 2 | 31 | China Medical University, ChinaOTHER | 0 | Jan 29, 2026 | clinicaltrials |
| NCT05036434 | Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma(ACCOMPLISH) | active not recruiting | Phase 2 | 30 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07357532 | Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD | not yet recruiting | Phase 2 | 44 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04505553 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | completed | Phase 2 | 78 | University of WashingtonOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03575793 | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 39 | Salma SabbourOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05001971 | Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy | completed | Phase 2 | 65 | Hunan Cancer HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03891784 | Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors | active not recruiting | Phase 2 | 20 | University of WashingtonOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04362436 | TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets(ArTisaN) | completed | Phase 2 | 24 | Imperial College LondonOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05594290 | Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery(MERCURY) | active not recruiting | Phase 2 | 36 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05987176 | Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases(NELMAS) | terminated | Phase 2 | 1 | Imperial College LondonOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06232564 | A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs(PELICAN) | active not recruiting | Phase 2 | 20 | Imperial College LondonOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07337447 | Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)(REWENEC 01) | not yet recruiting | Phase 2 | 122 | Hospices Civils de LyonOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT07321574 | A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors(ABP1011T-03) | recruiting | Phase 2 | 110 | Shanghai AB PharmaTech Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT05978284 | Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 54 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07038096 | ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 350 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07141264 | Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy | recruiting | Phase 2 | 32 | Tang-Du HospitalOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03600233 | Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors | active not recruiting | Phase 2 | 34 | TaiRx, Inc.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT03290079 | Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors | completed | Phase 2 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT05450965 | Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | recruiting | Phase 2 | 37 | University of Maryland, BaltimoreOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06926634 | Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs) | recruiting | Phase 2 | 32 | Washington University School of MedicineOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07289048 | A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression | not yet recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Dec 17, 2025 | clinicaltrials |
| NCT04696575 | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | recruiting | Phase 2 | 28 | Roswell Park Cancer InstituteOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05040360 | Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | recruiting | Phase 2 | 141 | SWOG Cancer Research NetworkNETWORK | 3 | Dec 15, 2025 | clinicaltrials |
| NCT07279532 | Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System | not yet recruiting | Phase 2 | 35 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Dec 12, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT06758700 | Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Feb 12, 2026source: clinicaltrials